MLNR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL73309	1.00	20/20
SCHEMBL73721	1.00	20/20
SCHEMBL73725	1.00	20/20
SCHEMBL75374	1.00	20/20
SCHEMBL75339	0.89	20/20
SCHEMBL74051	0.88	20/20
SCHEMBL73324	0.87	20/20
SCHEMBL91186	0.87	20/20
SCHEMBL73811	0.87	20/20
SCHEMBL75370	0.85	20/20
SCHEMBL73797	0.85	20/20
SCHEMBL74034	0.84	20/20
SCHEMBL73783	0.84	20/20
SCHEMBL73769	0.83	20/20
SCHEMBL74022	0.83	20/20
SCHEMBL74027	0.83	20/20
SCHEMBL73745	0.82	20/20
SCHEMBL73747	0.79	20/20
SCHEMBL75373	0.72	20/20
SCHEMBL74031	0.71	20/20

Clinical trials — most relevant to MLNR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Using Azithromycin Versus Placebo With Dexamethasone in Prevention of Post-spinal Nausea and Vomiting.	PHASE4	UNKNOWN
Colonic Motor Patterns in Healthy Volunteers	PHASE4	COMPLETED
Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation	PHASE4	COMPLETED
The Effect of Motilin on the Frequency and Amount of Food Intake	PHASE4	ENROLLING_BY_INVITATION
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)	PHASE3	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer	PHASE2	COMPLETED
Effect of GSK962040 on Oesophageal Function	PHASE1	COMPLETED
A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers	PHASE1	COMPLETED
Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics	PHASE1	COMPLETED
Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects	PHASE1	COMPLETED
Effects of Exendin(9-39) on Gastroduodenal Motility	PHASE1	COMPLETED
Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.	PHASE1	COMPLETED
Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways	nan	COMPLETED
Ghrelin and Gastric Emptying in Children With Functional Dyspepsia	nan	COMPLETED
Gastroparesis Registry 3	nan	COMPLETED
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use	nan	COMPLETED
Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia	nan	COMPLETED
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)	nan	COMPLETED
Exploring the Role of taVNS in Nausea Management	nan	RECRUITING
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention	nan	NOT_YET_RECRUITING
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	nan	RECRUITING
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake	nan	COMPLETED
Reflexology Socks and Opioid-induced Constipation	nan	COMPLETED
Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine	nan	COMPLETED
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling	nan	COMPLETED
Gastrointestinal Hormonal Regulation of Obesity	nan	COMPLETED
The Effect of Chlorpromazine on Esophageal Sensitivity in Healthy Volunteers.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MLNR binder may also engage these)

Protein	Name	Similarity
Q8HYC3	—	0.969	Q8HYC3 →
UTS2R	Urotensin-2 receptor	0.965	landscape →
A5A4K9	—	0.961	A5A4K9 →
Q95254	—	0.958	Q95254 →
S1PR5	Sphingosine 1-phosphate receptor 5	0.953	landscape →
SSTR3	Somatostatin receptor type 3	0.953	landscape →
Q9JKM5	—	0.952	Q9JKM5 →
P30796	—	0.952	P30796 →
P30552	—	0.952	P30552 →
SSTR4	Somatostatin receptor type 4	0.952	landscape →
O08725	—	0.952	O08725 →
GPR6	G-protein coupled receptor 6	0.951	landscape →
GHSR	Growth hormone secretagogue receptor type 1	0.951	landscape →
Q91X56	—	0.950	Q91X56 →
P56481	—	0.950	P56481 →
A5A4L1	—	0.950	A5A4L1 →
P32307	—	0.950	P32307 →
P51651	—	0.949	P51651 →
Q684M3	—	0.949	Q684M3 →
GPR27	Probable G-protein coupled receptor 27	0.948	landscape →
AVPR2	Vasopressin V2 receptor	0.948	landscape →
P49220	—	0.948	P49220 →
O77808	—	0.948	O77808 →
CCKBR	Gastrin/cholecystokinin type B receptor	0.947	landscape →
PTGER1	Prostaglandin E2 receptor EP1 subtype	0.947	landscape →
Q9BDQ5	—	0.946	Q9BDQ5 →
O54897	—	0.946	O54897 →
NPFFR1	Neuropeptide FF receptor 1	0.945	landscape →
Q99P50	—	0.945	Q99P50 →
P2RY2	P2Y purinoceptor 2	0.945	landscape →